These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31755788)

  • 21. Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.
    Huynh S; Lheure C; Franck N; Goldman-Lévy G; Aractingi S; Dupin N; Kramkimel N; Guégan S
    Melanoma Res; 2020 Jun; 30(3):317-320. PubMed ID: 32053122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma.
    Saint-Jean M; Le Moigne M; Daguze J; Bossard C; Peuvrel L; Quéreux G; Dréno B
    Acta Derm Venereol; 2018 Apr; 98(5):530-531. PubMed ID: 29362816
    [No Abstract]   [Full Text] [Related]  

  • 23. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
    Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
    Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
    Avila C; Hoffman K; Milani-Nejad N; Pootrakul L
    Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib.
    Sawada H; Kanehisa F; Katoh N; Asai J
    J Dermatol; 2020 Jan; 47(1):e7-e8. PubMed ID: 31587335
    [No Abstract]   [Full Text] [Related]  

  • 28. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
    Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
    [No Abstract]   [Full Text] [Related]  

  • 29. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
    Hussar DA; Kaminski JL
    J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
    [No Abstract]   [Full Text] [Related]  

  • 30. Acute intraventricular conduction disorder due to combination therapy with dabrafenib and trametinib for metastatic melanoma: Case report.
    Yamamura K; Matsushita S; Aoki M; Kusumoto K
    J Dermatol; 2018 May; 45(5):e120-e121. PubMed ID: 29178523
    [No Abstract]   [Full Text] [Related]  

  • 31. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
    N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
    Cocorocchio E; Pala L; Battaglia A; Gandini S; Peccatori FA; Ferrucci PF
    Acta Oncol; 2018 Aug; 57(8):1131-1133. PubMed ID: 29526130
    [No Abstract]   [Full Text] [Related]  

  • 33. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
    Jansen YJ; Janssens P; Hoorens A; Schreuer MS; Seremet T; Wilgenhof S; Neyns B
    Melanoma Res; 2015 Dec; 25(6):550-4. PubMed ID: 26512791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome.
    Perico L; Mandalà M; Schieppati A; Carrara C; Rizzo P; Conti S; Longaretti L; Benigni A; Remuzzi G
    Am J Kidney Dis; 2017 Jul; 70(1):145-150. PubMed ID: 28242136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma.
    Eser Öztürk H; Süllü Y
    Turk J Ophthalmol; 2020 Mar; 50(1):50-52. PubMed ID: 32167264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].
    Lüdeke I; Terheyden P; Grisanti S; Lüke M
    Ophthalmologe; 2016 Oct; 113(10):861-863. PubMed ID: 26873702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing the skin toxicities from new melanoma drugs.
    Mavropoulos JC; Wang TS
    Curr Treat Options Oncol; 2014 Jun; 15(2):281-301. PubMed ID: 24867225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erythema Nodosum-Like Panniculitis as a False-Positive 18F-FDG PET/CT in Advanced Melanoma Treated With Dabrafenib and Trametinib.
    Martínez-Rodríguez I; García-Castaño A; Quirce R; Jiménez-Bonilla J; Banzo I
    Clin Nucl Med; 2017 Jan; 42(1):44-46. PubMed ID: 27775948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.